A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Latest Information Update: 23 Aug 2024
At a glance
- Drugs Ivosidenib (Primary)
- Indications Cholangiocarcinoma
- Focus Registrational; Therapeutic Use
- Acronyms ClarIDHy
- Sponsors Agios Pharmaceuticals
- 01 May 2024 Results of pharmacokinetic (PK)/pharmacodynamic (PD) findings from the phase III ClarIDHy study and any association between PK/PD parameters and treatment outcomes in this population, published in the Cancer Chemotherapy and Pharmacology
- 11 May 2023 According to a CStone Pharmaceuticals media release, Servier, a partner of CStone Pharmaceuticals announced European Commission approved Tuosuvo (ivonib tablets) for the treatment of patients with IDH1-mutated acute myeloid leukemia and cholangiocarcinoma.
- 15 Mar 2023 According to a CStone Pharmaceuticals media release, MAA approval is expected in E.U. in 2023.